IMCR - Immunocore Short-Term Debt to Capital

Symbol and logo of brand Immunocore PLC (IMCR)

The share price of Immunocore Holdings plc (IMCR) visualized below on the GURU.Markets platform is 0.00. The company, led by Bakhtiar Karimi, is implementing cutting-edge developments in cancer therapy. The logistics model relies on a network of global distribution centers to maintain the quality of perishable biologics. Business stability is guaranteed by a staff of leading T-cell experts and an aggressive search for specialized clinical trial professionals.

Current Liabilities to Capital: Immunocore PLC (IMCR) for 07/04/2022 - 11/01/2026

Summary analytical data breakdowns for immunocore.com (IMCR)

- stock value and consensus price forecast:
Price Chart Immunocore PLC|IMCR - Broker Consensus Forecast
- market capitalization statistics:
Market Capitalization Immunocore Holdings plc|IMCR - Real Price to Acquire Entire Company
- book capitalization information:
Net Assets per Single Share Immunocore|IMCR - Total Stockholders' Equity|Market Value to Book Value Ratio immunocore.com|IMCR - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Immunocore Holdings plc|IMCR - Long-Term Liabilities to Capital|Short-Term Debt to Capital Immunocore|IMCR - Company Total Indebtedness|Debt to Book Value Immunocore Holdings plc|IMCR - Long-Term Debt|Company Current Liabilities Immunocore|Quick Ratio immunocore.com
- company profitability and valuation multiples indicators:
IMCR - Net Financial Result
Initial company analysis:Immunocore PLC IMCR
Signature product of immunocore.com

This indicator determines the proportion of short-term borrowings relative to equity, assessing the liquidity and financial stability of the balance sheet. By analyzing the trend of short-term liabilities to equity, an investor can gauge the company's dependence on rapid refinancing, which is critically important for Immunocore Holdings plc (IMCR), given the colossal costs of multi-year clinical trials and the launch of complex TCR drug production.

Competitors of Immunocore Holdings plc (IMCR)

Short-Term Debt to Equity ImmunityBio Corp (IBRX)|Janux Corp - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital RCUS (Arcus Biosciences, Inc.)|ZYME - Short-Term Debt to Equity Ratio|TNGX - Short-Term Debt to Equity|Current Liabilities to Capital Iovance Biotherapeutics Inc|Immatics Corp (IMTX) - Short-Term Debt to Equity|XNCR (Xencor Inc.) - Short-Term Debt to Equity|Short-Term Debt to Equity Compass Therapeutics|Current Liabilities to Capital replimune.com REPL|Short-Term Debt to Capital LYEL|Innate Pharma SA (IPHA) - Short-Term Indebtedness to Equity|Pyxis Oncology - Short-Term Debt to Equity Ratio|Compugen Ltd (CGEN) - Current Liabilities to Capital|IOBT: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital STRO (sutrobio.com)|INKT: Short-Term Debt to Capital|HOWL - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Immix Biopharma Inc.|Short-Term Debt to Equity Ratio alxoncology.com (ALXO)|Short-Term Debt to Equity Cue Biopharma (CUE)|Short-Term Debt to Equity Ratio pdsbiotech.com PDSB|Sonnet BioTherapeutics Holdings - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital MAIA Biotech MAIA|LIMN - Short-Term Debt to Equity|LVTX (LAVA Therapeutics N.V.) - Short-Term Debt to Capital Ratio|NextCure, Inc. (NXTC) - Short-Term Debt to Equity|Current Liabilities to Capital Leap Therapeutics (LPTX)|Short-Term Debt to Equity Ratio INTS|SNSE - Short-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio TOVX (Synthetic Biologics)|Short-Term Loans to Capital Ratio GRTS|Short-Term Debt to Capital KA (Kineta, Inc.)|Ratio of Short-Term Indebtedness to Capital NEXI|Turnstone Biologics Corporation - Short-Term Debt to Capital|Current Liabilities to Capital Vaccinex Inc.|Harpoon Tx (HARP) - Short-Term Debt to Equity